High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma

Qun Li1,2 | Zhisen Shen1,2 | Zhenhua Wu3 | Yi Shen1,2 | Hongxia Deng1,2 | Chongchang Zhou1,2 | Huigao Liu4

1Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China
2Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital affiliated to Ningbo University, Ningbo, Zhejiang, China
3Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, Zhejiang, China
4Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Zhenhai Longsai Hospital, Ningbo, Zhejiang, China

Correspondence
Chongchang Zhou and Huigao Liu,
Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China.
Emails: zhou90070900709@gmail.com (C.Z.) and 8658259386582593@gmail.com (H.L.)

Funding information
National Natural Science Foundation of China, Grant/Award Number: 81670920; Zhejiang Provincial Natural Science Foundation of China, Grant/Award Number: LY14H160003, LY15H130003 and LY19H160090; Medical and Health Science Research Foundation of Zhejiang Province, Grant/Award Number: 2016KYB272, 2018RC063 and 2019ZD018; Medical and Health Training Project of Zhejiang Province, Grant/Award Number: 2014PYA017 and 2015RCB025; Scientific Innovation Team Project of Ningbo, Grant/Award Number: 2012B82019; Ningbo Natural Science Foundation, Grant/Award Number: 2013A610217, 2015A610221, 2017A610236, 2018A610363 and 2018A610361; Huimin Technology Research and Development Projects of Ningbo, Grant/Award Number: 2015C50026; Ningbo Health Branding Subject Fund, Grant/Award Number: PPKK2018-02

Abstract
Background: Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) plays a critical role in modulating the extracellular matrix and promoting tumor progression in various cancers. However, the association between P4HA1 and head and neck squamous cell carcinomas (HNSCC) has not been thoroughly elucidated to date.

Methods: P4HA1 mRNA and protein expression in cancer and normal tissues were analyzed using The Cancer Genome Atlas (TCGA), Gene Expression Omnibus, and Human Protein Atlas databases. Quantitative PCR was applied to determine P4HA1 mRNA expression levels in 162 paired HNSCC and adjacent normal tissues. The cBioPortal for Cancer Genomics was utilized to explore P4HA1 genetic alterations in HNSCC. Then, KEGG analysis of P4HA1 co-expressed genes in HNSCC was conducted using ClueGo in Cytoscape.

Results: P4HA1 mRNA and protein levels were significantly increased in HNSCC tissues compared with normal tissues. High P4HA1 expression in HNSCC tissues was significantly associated with tumor category, lymphatic metastasis and pathological stage. The area under summary receiver operating characteristic curve of TCGA and validation cohort was 0.887 and 0.883, respectively. Moreover, elevated P4HA1 expression was associated with unfavorable OS (HR: 1.728, P = .001) and RFS (HR: 2.025, P = .002) in HNSCC patients.

Conclusions: This integrated analysis provides strong evidence that increasing P4HA1 expression is significantly associated with the carcinogenesis of HNSCC. Additionally, high P4HA1 expression serves as both diagnostic biomarker and independent prognostic factor for poor OS and RFS in HNSCC patients.
1 | INTRODUCTION

Head and neck cancers represent the sixth most common cancer worldwide. The vast majority (greater than 90%) are head and neck squamous cell carcinomas (HNSCC), such that the term head and neck cancer refers to cancer arising from the epithelium lining the oropharynx and exhibiting microscopic evidence of squamous differentiation. According to the latest report of the International Agency for Research on Cancer, approximately one million new HNSCC patients were estimated to be clinically diagnosed in 2018 with greater than 542,943 deaths worldwide. The risk for developing HNSCC is associated with several traditional etiological factors, including cigarette smoking and alcohol abuse. Increasing evidence also demonstrates that infection with a high-risk human papillomavirus (HPV) strain is associated with HNSCC and is an important favorable prognostic factor, especially for oral cavity and oropharynx cancer. Although the recent diagnostic and therapeutic strategies have yielded some significant improvements, the 5-year survival rate for HNSCC patients over the last decade remained at approximately 50%. Although multiple molecular mechanisms are associated with HNSCC initiation, growth, invasion, and metastasis, the exact pathogenesis of tumorigenesis remains unclear. Development of new technologies, such as microarray technology and next-generation sequencing, has allowed for collection of large amounts of data to explore the key genes in the pathogenesis of HNSCC, such as CDKN2A, CDH1, and EGFR. Therefore, the identification of oncogenic drivers and potential therapeutic targets is crucial for both early diagnosis and effective treatment for HNSCC.

Tumor hypoxia is an essential characteristic of the neoplastic microenvironment that may be correlated with cell proliferation, apoptosis, differentiation, vascularization/angiogenesis, genetic instability, tumor metabolism, tumor immune responses, and invasion and metastasis. Under hypoxic microenvironments, hypoxia inducible factor-1 (HIF-1) promotes extracellular matrix (ECM) remodeling by inducing prolyl 4-hydroxylase subunit alpha 1 (P4HA1), prolyl 4-hydroxylase subunit alpha 2 (P4HA2), and procollagen-lysin, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) expression, leading to changes in cancer cell morphology, adhesion and motility that enhance invasion and metastasis. Located at 10q22.1, P4HA1 encodes an active catalytic subunit of prolyl 4-hydroxylase that catalyzes the formation of 4-hydroxyprolene in collagen, which is essential to the formation and stabilization of the triple helical domain of newly synthesized procollagen chains. P4HA1 was identified as hypoxia-responsive gene and plays a critical role in regulating collagen biosynthesis. Previous evidence suggested that P4HA1 overexpression plays a critical role in cancer progression. Hu et al reported that high P4HA1 expression is correlated with the malignancy of gliomas and could serve as a prognostic indicator for patients with high-grade gliomas. In human breast cancer, P4HA1 plays an essential role in enhancing invasion and metastasis and is significantly associated with decreased patient survival. However, until now, the association between P4HA1 and HNSCC as well as its clinical value was not clearly delineated.

In this study, we evaluated the expression of P4HA1 in HNSCC and its clinical value. In addition, we also investigated the enrichment of P4HA1 co-expressed genes in KEGG pathways to explore its underlying mechanism in HNSCC.

2 | MATERIALS AND METHODS

2.1 | Bioinformatic analysis using UCSC Xena browser

P4HA1 mRNA expression and details of the clinicopathological characteristics of patients with primary HNSCC in TCGA cohort (Project Id: TCGA-HNSC) were obtained by using the University of California Santa Cruz (UCSC) Xena browser (https://xenabrowser.net/).

2.2 | Comparison of P4HA1 gene expression between tumor vs non-tumor samples using Gene Expression Omnibus database

P4HA1 mRNA expression in HNSCC samples compared with normal tissue was also analyzed using published databases (GSE6631) downloaded from Gene Expression Omnibus (GEO). In the GSE6631 database, data for gene expression profiling of 22 paired HNSCC samples and corresponding adjacent normal tissues were obtained.

2.3 | Specimens collection

To validate the findings of the bioinformatics analysis, 162 HNSCC tissues and their adjacent non-tumorous tissues were collected from the Ningbo Medical Centre Lihuili Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, from February 2014 to November 2018. None of the patients underwent treatment before operation. Each specimen was histopathologically confirmed by two pathologists. All specimens were preserved in RNA-fixer Reagent (Bioteke) and stored at −80°C until further experiments. This study was approved by the Human Research Ethics Committee of Ningbo
2.4 | Total RNA extraction and quantitative real-time PCR

Total RNA was extracted from 162 paired HNSCC and normal tissues using the TRIzol reagent (Invitrogen), then reverse transcribed into cDNA by GoScript Reverse Transcription (RT) System (Promega) following the manufacturer’s instructions. Real-time quantitative reverse transcription-polymerase chain reaction quantitative real-time PCR (qRT-PCR) was performed as previously described. The housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a normalize control. The primers were synthesized by Huada Biotech. The sequences of the PCR primers were as follows: 5’-AGTACAGCGACAAAGATCCAG-3’ and 5’-CTCCAACTCACTCCACTCAGTA-3’ for P4HA1; 5’-CCATGGAAAGGCTGGGG-3’, and 5’-CAAAGTTGTCATGGATGACC-3’ for GAPDH. The conditions of thermal cycling were as follows: 95°C at 10 minutes for a hot-start, 45 amplification cycles at 95°C for 15 seconds, 55°C for 35 seconds, and 70°C for 30 seconds. The expression of P4HA1 was calculated using the ΔCt method. Larger ΔCt value indicates lower expression. All experiments were performed in triplicate.

2.5 | Immunohistochemistry staining

P4HA1 protein expression levels in HNSCC tissues and in normal tissues were explored using immunohistochemistry (IHC) staining data from the Human Protein Atlas (HPA; http://www.proteinatlas.org/).

2.6 | P4HA1 genetic alteration analysis using cBioPortal for Cancer Genomics and KEGG analysis using ClueGo in Cytoscape

P4HA1 genetic alterations in HNSCC were examined using cBioPortal for Cancer Genomics (http://www.cbioportal.org/). The associations between P4HA1 genetic alterations and overall survival (OS) as well as disease-free survival (DFS) in HNSCC patients were assessed by generating Kaplan-Meier survival curves. The genes co-expressed with P4HA1 in HNSCC were defined as (|Pearson’s r| ≥ 0.4 and |Spearman’s r| ≥ 0.4). Then, the co-expressed genes were loaded into ClueGo in Cytoscape for analysis of KEGG pathways. Only pathways with a P-value ≥ 0.05 were included.

2.7 | Statistical analysis

All statistical analysis was performed using Statistical Program for Social Sciences (SPSS) 20.0 software (SPSS Inc) and R 3.1.2 software (https://www.r-project.org/), which were also used to generate figures. For comparisons of P4HA1 expression between groups, independent Student’s t test and one-way analysis of variance (one-way ANOVA) tests were employed as appropriate. Receiver operating characteristic (ROC) analysis was used to assess the diagnostic value of P4HA1 expression for HNSCC. The cut-off point was defined as the maximum Youden index. HNSCC patients with integrated survival data were divided into high and low P4HA1 expression groups according to the maximum Youden index based on ROC curves for death and recurrence detection in HNSCC patients. Kaplan-Meier curves of overall survival (OS) and recurrent-free survival (RFS) after initial therapy were generated, and log-rank tests were performed to evaluate the difference between the survival curves. Univariate and multivariate Cox

**FIGURE 1** P4HA1 expression levels are significantly elevated in HNSCC tissues compared with normal tissues using public databases. A-B, Heatmap (A) and plot (B) showing P4HA1 expression in HNSCC tissue and normal tissue using TCGA database. C, P4HA1 expression in HNSCC tissue and normal tissue using GEO database. N, Sample number
regression analyses were performed to determine the independent prognostic value of P4HA1 expression in terms of OS and RFS in HNSCC patients. *P*-value < .05 was considered to be statistically significant.

### 3 | RESULTS

#### 3.1 | P4HA1 expression is significantly elevated in HNSCC tissues

By comparing P4HA1 mRNA expression using the RNA-Seq data of 520 HNSCC tissues and normal tissues in TCGA, we revealed that HNSCC tissues exhibited significantly elevated P4HA1 mRNA expression compared with normal tissues (*P* = 1.64E-23; Figure 1A,B), consistent with our findings using GEO data (*P* = 6.16E-04; Figure 1C). The qRT-PCR analysis using the 162 paired HNSCC samples confirmed that P4HA1 mRNA expression levels were significantly upregulated in HNSCC tissues compared with adjacent normal tissues (*P* = 1.41E-40, Figure 2). We further explored P4HA1 protein expression in HNSCC tissues and normal tissues using the HPA database. Immunohistochemical staining images revealed that P4HA1 exhibited high expression in HNSCC tissues (Figure 3A). In comparison, oral mucosa exhibited medium P4HA1 expression (Figure 3B).

#### 3.2 | Association of P4HA1 expression with some clinical features of HNSCC

Then, we analyzed the association between P4HA1 mRNA expression levels and clinicopathological characteristics of patients with HNSCC. As shown in Table 1, high P4HA1 expression in HNSCC tissues was significantly associated with alcohol consumption (*P* = .019), tumor location (*P* = .017), HPV infection (*P* = .011), tumor category (*P* = .006), lymphatic metastasis (*P* = .006), and pathological stage (*P* = .002).

### 3.3 | Diagnostic value of P4HA1 expression for HNSCC

We examined the diagnostic value of P4HA1 expression in HNSCC using ROC curves. An area under the ROC curve (AUC) closer to 1.0 signifies that the test exhibits more perfect discrimination. The maximum Youden index was used as a cut-off point. The result suggested that P4HA1 expression yielded an AUC of 0.887, a sensitivity of 88.8%, and a specificity of 78.1% using TCGA cohort (Figure 4A) and yielded an AUC of 0.883, a sensitivity of 78.4% and a specificity of 83.3% using our validation cohort (Figure 4B).

### 3.4 | High P4HA1 expression was an independent prognostic predictor of unfavorable OS and RFS in HNSCC patients

Using the maximum Youden index as cut-off point (10.665), we classified 517 HNSCC patients with integrated OS data into the high P4HA1 expression group (N = 173) and low P4HA1 expression group (N = 344). Kaplan-Meier curves and log-rank tests revealed that high P4HA1 expression was associated with significantly worse OS in HNSCC (*P* = 2.07E-5). In addition, 437 HNSCC patients with integrated RFS data were divided into high (N = 106) and low (N = 331) P4HA1 expression groups according to a cut-off value of 10.845. Kaplan-Meier curves and log-rank tests revealed that HNSCC patients in the high P4HA1 expression group exhibited significantly poorer RFS (*P* = .002).

In univariant Cox proportional hazards analysis, the results showed that elderly (hazard ratio (HR): 1.318, 95% confidence interval (CI): 1.003-1.731, *P* = .047), female (HR: 1.349, 95% CI: 1.014-1.796, *P* = .04), advanced stages (HR: 1.754, 95% CI: 1.203-2.558, *P* = .004), lymphatic metastasis (HR: 1.86, 95% CI: 1.343-2.576, *P* = 1.86E-04), and elevated P4HA1 expression (HR: 1.775, 95% CI: 1.358-2.321, *P* = 2.68E-05) were associated with unfavorable OS. Of note, we found that alcohol consumption (HR: 1.809, 95% CI: 1.130-2.896, *P* = .014), advanced stages (HR: 2.302, 95% CI: 1.249-4.242, *P* = .007), lymphatic metastasis (HR: 1.653, 95% CI: 1.062-2.573, *P* = .026), and high P4HA1 expression (HR: 1.865, 95% CI: 1.249-2.785, *P* = .002) were significantly associated with shorter RFS (Table 2). Multivariant Cox proportional hazard analysis was conducted to investigate the independent prognostic factors in terms of OS and RFS in HNSCC patients by adjusting only variables that exhibited significance in univariate analysis. We found that high P4HA1 expression (OS: HR: 1.728, 95% CI: 1.267-2.357, *P* = .001; RFS: HR: 2.025, 95% CI: 1.296-3.162, *P* = .002) was independent unfavorable prognostic factor in terms of OS and RFS in HNSCC patients (Figure 5).
3.5 | P4HA1 genetic alteration was associated with worse OS and DFS in HNSCC patients

The cBioPortal for Cancer Genomics was utilized to explore P4HA1 genetic alterations in HNSCC. P4HA1 was only altered in 8 samples, including 504 sequenced HNSCC patients from the Cancer Genome Atlas Research (Figure 6). Then, we also evaluated the association between P4HA1 genetic alteration and survival in HNSCC patients. Survival curves indicated that HNSCC patients with P4HA1 genetic alterations exhibited significantly worse OS (log-rank \( P = .025 \)) and DFS (log-rank \( P = .007 \)).

3.6 | KEGG analysis based on P4HA1 co-expressed genes

By data mining using cBioPortal for Cancer Genomics, we identified 282 co-expressed genes with P4HA1 in HNSCC. To further investigate the possible signaling pathways that P4HA1 might be involved in, P4HA1 co-expressed genes in HNSCC were subjected to KEGG pathway analysis. In HNSCC, P4HA1 co-expressed genes were enriched in the HIF-1 signaling pathway, focal adhesion, regulation of actin cytoskeleton, protein processing in endoplasmic reticulum, vibrio cholera infection, lysosome, lysine degradation,
glycolysis/gluconeogenesis, and other types of O-glycan biosynthesis (Figure 7).

4 | DISCUSSION

Collagens are the major structural extracellular matrix (ECM) proteins and form fibers or networks in tumor tissues to support the tumor microenvironment and play crucial roles in carcinogenesis. 20,21 P4HA1 is a key intracellular enzyme to catalyze the formation of 4-hydroxyproline that is essential for proper three-dimensional folding of newly synthesized procollagen chains, maintaining ECM homeostasis. 24 Accumulating evidence indicates that increased P4HA1 is associated with the initiation, invasion, and metastasis of many human cancers, including hepatocellular carcinoma, 22 breast cancer, 27 and prostate cancer. 28 However, the association of P4HA1 with HNSCC remains uninvestigated. In the present study, significantly increased P4HA1 mRNA levels were observed in HNSCC tissues compared with nontumor tissues using TCGA database, which is consistent with the analysis results of the GEO database. Furthermore, the HPA database validated that P4HA1 protein levels were elevated in HNSCC compared with surrounding normal tissue and demonstrated that P4HA1 was mainly localized to the endoplasmic reticulum and slightly localized to the mitochondria and vesicles. All these results suggested that P4HA1 plays an important role in HNSCC transformation.

The history of high alcohol consumption is a crucial factor for increased the risk of HNSCC. 24 In this study, using RNA-seq data in TCGA-HNSC, we found that increased P4HA1 expression was significantly correlated with alcohol consumption, suggesting that alcohol might contribute to HNSCC by inducing P4HA1 expression. Accumulating evidence indicates that HPV infection is an important risk factor for HNSCC. HPV-positive HNSCCs and HPV-negative HNSCCs differ with respect to the molecular mechanisms underlying their oncogenic processes. 4 HPV-positive cancers are more susceptible to chemotherapy and radiation with better prognosis compared with HPV-negative patients. 25,26 Studies have consistently demonstrated that most HNSCCs with HPV detected in the tumor are from the oral cavity and oropharynx, 27 and HPV is driving the increasing incidence of oral cavity and oropharyngeal cancer over the past 30 years. 28,29 Consistent with prior reports that integration of HPV into the genome results in altered DNA copy number and mRNA transcript abundance and splicing, 30 our analysis demonstrated that downregulated P4HA1 was more frequently found in tumors located in the oral cavity and oropharynx as well as in HPV-positive patients, indicating that HPV infection contributes to HNSCC by inhibiting P4HA1 expression. Moreover, P4HA1 was overexpressed in HNSCC at advanced stages and with lymphatic metastasis compared with early stage disease and no lymphatic metastasis, suggesting the involvement of P4HA1 in the tumorigenesis and metastatic progression of HNSCC.

One of the most important issues concerning cancer patients is how to screen and diagnose at an early stage. Screening for HNSCC depends on clinical symptoms and imaging examinations (laryngoscopy, computed tomography, magnetic resonance imaging, and positron emission tomography), and a definite diagnosis depends on biopsy and histopathological examination. 1 However, given the nonspecificity of symptoms in the early stage, the early detection of HNSCC remains unsatisfactory. In the present study, we constructed ROC curves and calculated the AUC to determine the diagnostic value of P4HA1 for HNSCC. The AUC value of TCGA and validation cohort was 0.887 and 0.883, respectively, signifying greater diagnostic accuracy compared with conventional cancer-related biomarkers, such as carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC Ag), TPS (tissue polypeptide specific antigen), and Cyfra 21.1. 31,32 These results suggest that P4HA1 expression levels might represent a promising diagnostic biomarker for HNSCC.

### Table 1: Association between P4HA1 expression and clinicopathological features of HNSCC patients

| Characteristics         | N   | Mean ± SD       | P-value |
|-------------------------|-----|-----------------|---------|
| Gender                  |     |                 |         |
| Female                  | 136 | 10.168 ± 0.877  | 0.208   |
| Male                    | 384 | 10.276 ± 0.858  |         |
| Age                     |     |                 |         |
| <60 y                   | 233 | 10.229 ± 0.827  | 0.63    |
| ≥60 y                   | 286 | 10.265 ± 0.894  |         |
| Smoking history         |     |                 |         |
| No                      | 117 | 10.149 ± 0.894  | 0.199   |
| Yes                     | 391 | 10.266 ± 0.853  |         |
| Alcohol history         |     |                 |         |
| No                      | 162 | 10.115 ± 0.892  | 0.019   |
| Yes                     | 347 | 10.306 ± 0.842  |         |
| Histologic grade        |     |                 |         |
| G1 + 2                  | 366 | 10.199 ± 0.830  | 0.084   |
| G3 + 4                  | 132 | 10.350 ± 0.927  |         |
| Tumor site              |     |                 |         |
| Oral cavity + oropharynx| 394 | 10.197 ± 0.870  | 0.017   |
| Hypopharynx + larynx    | 126 | 10.408 ± 0.824  |         |
| HPV status              |     |                 |         |
| Negative                | 73  | 10.328 ± 0.724  | 0.011   |
| Positive                | 38  | 9.942 ± 0.798   |         |
| Tumor category          |     |                 |         |
| Tis/T1/T2               | 185 | 10.104 ± 0.853  | 0.006   |
| T3/T4                   | 273 | 10.330 ± 0.850  |         |
| Lymphatic metastasis    |     |                 |         |
| No                      | 176 | 10.111 ± 0.820  | 0.006   |
| Yes                     | 244 | 10.341 ± 0.862  |         |
| Pathological stage      |     |                 |         |
| I + II                  | 101 | 10.021 ± 0.812  | 0.002   |
| III + IV                | 347 | 10.329 ± 0.875  |         |

Abbreviation: N, sample number.
Despite current treatment regimens with curative intent, including surgery, radiotherapy and chemotherapy, local or distant recurrence rates remain high, and the 5-year overall survival rate of HNSCC patients is less than 50%. Emerging therapeutic strategies, such as anti-EGFR antibody (cetuximab) and anti-PD-1 antibodies (pembrolizumab and nivolumab) that have recently been approved for the

**FIGURE 4** Receiver operating characteristic (ROC) curves to assess the diagnostic value of P4HA1 expression in HNSCC patients. The area under the curve (AUC) was 0.887 based on TCGA cohort. The area under the curve (AUC) was 0.883 based on our validation cohort. The arrow points to the intercept.

**TABLE 2** Univariate and multivariate analysis of overall survival and recurrent-free survival in HNSCC patients

| Characteristics                  | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR  | 95% CI    | P value | HR  | 95% CI    | P value |
| Overall survival                 |     |           |         |     |           |         |
| Age (≥60 y vs <60 y)             | 1.318 | 1.003-1.731 | .047    | 1.223 | 0.891-1.679 | .214    |
| Gender (female vs male)          | 1.349 | 1.014-1.796 | .04     | 1.372 | 0.978-1.926 | .067    |
| Smoking history (yes vs no)      | 1.123 | 0.803-1.572 | .498    |       |           |         |
| Alcohol history (yes vs no)      | 0.942 | 0.709-1.252 | .68     |       |           |         |
| Histologic grade (G3/4 vs G1/2)  | 0.867 | 0.637-1.180 | .419    |       |           |         |
| Pathologic stage (III/IV vs I/II)| 1.754 | 1.203-2.558 | .004    | 1.878 | 1.055-3.345 | .032    |
| Pathologic N (N1/2/3 vs N0)      | 1.86 | 1.343-2.576 | 1.86E-04 | 1.422 | 0.973-2.078 | .069    |
| HPV (positive vs negative)       | 0.856 | 0.420-1.746 | .67     |       |           |         |
| P4HA1 expression (high vs low)   | 1.775 | 1.358-2.321 | 2.68E-05 | 1.728 | 1.267-2.357 | .001    |

**Recurrence-free survival**

|                                  | HR  | 95% CI    | P value | HR  | 95% CI    | P value |
|----------------------------------|-----|-----------|---------|-----|-----------|---------|
| Age (≥60 y vs <60 y)             | 1.291 | 0.878-1.899 | .194    |     |           |         |
| Gender (female vs male)          | 1.118 | 0.714-1.751 | .626    |     |           |         |
| Smoking history (yes vs no)      | 0.973 | 0.626-1.513 | .904    |     |           |         |
| Alcohol history (yes vs no)      | 1.809 | 1.130-2.896 | .014    | 1.36 | 0.827-2.236 | .226    |
| Histologic grade (G3/4 vs G1/2)  | 0.821 | 0.526-1.281 | .384    |     |           |         |
| Pathologic stage (III/IV vs I/II)| 2.302 | 1.249-4.242 | .007    | 1.514 | 0.721-3.179 | .274    |
| Pathologic N (N1/2/3 vs N0)      | 1.653 | 1.062-2.573 | .026    | 1.19 | 0.709-1.996 | .511    |
| HPV (positive vs negative)       | 0.914 | 0.343-2.438 | .858    |     |           |         |
| P4HA1 expression (high vs low)   | 1.865 | 1.249-2.785 | .002    | 2.025 | 1.296-3.162 | .002    |

Abbreviations: CI, confidence interval; HR, hazard ratio.
Treatment of advanced and metastatic HNSCC, are promising options for the management of high-risk patients. However, predicting high-risk HNSCC patients remains a challenge for both the clinician and the pathologist. Tumor diameter, lymphatic metastasis, distal metastasis, and clinical stage are vital factors affecting tumor patient outcomes; however, these factors are unable to absolutely justify clinical application due to heterogeneous molecular mechanisms and clinical behaviors of HNSCC. Therefore, reliable prognostic biomarkers are urgently needed to identify HNSCC patients at risk of disease recurrence and subsequent death. Recently, dysregulation of P4HA1 expression was reported to promote tumor progression and associated with unfavorable prognosis in various cancers, including gliomas, breast cancer, and prostate cancer. With regard to the findings in the present study, the log-rank test and univariate Cox proportional hazard analysis showed that high P4HA1 expression was correlated with inferior OS and RFS of HNSCC patients, and these findings are consistent with previous report. Future multivariate Cox proportional hazard analysis confirmed that both elevated P4HA1 and advanced stages were dependent poor prognostic factors for OS and RFS of HNSCC patients after adjusting for age, gender, smoking behavior, alcohol consumption, and histologic grade. Taken together, the present study indicates that P4HA1 expression may be of great value for tailoring of

**FIGURE 5**  Association between P4HA1 expression and survival in HNSCC. A, High P4HA1 expression is associated with poor OS in HNSCC patients; B, High P4HA1 expression is associated with poor RFS in HNSCC patients.

**FIGURE 6**  P4HA1 genetic alterations in HNSCC and its correlation with prognosis of HNSCC patients in OS and DFS. A, P4HA1 is altered in 1.6% (8/504) of sequenced HNSCC patients. B, P4HA1 genetic alterations were associated with significantly worse overall survival; C, P4HA1 genetic alterations were associated with significantly worse disease-free survival.
individual therapies and risk stratification of recurrence and subsequent death, which might help these patients benefit from an intensified first-line treatment and surveillance.

Based on large HNSCC samples in TCGA using cBioPortal for Cancer Genomics, we found that although P4HA1 genetic alteration was less frequent in HNSCC (8/504), its alteration was associated with significantly worse overall survival and disease-free survival. Given that elevated P4HA1 was dependent poor prognostic biomarker for OS and RFS of HNSCC patients, we hypothesized that P4HA1 genetic alterations might increase its expression level, which should be confirmed in further investigations. In HNSCC, P4HA1 co-expressed genes were additionally enriched in some cancer-related and metabolism-related pathways, such as HIF-1 signaling pathway, lysine degradation pathway, and gluconeogenesis pathway. These results can provide novel insight HNSCC pathogenesis. In breast cancer, HIF-1 mediates increasing P4HA1 expression in conditions of hypoxic stress, resulting in fibrillar collagen deposition and the induction of a more invasive cell phenotype.17 However, several limitations of our study should be considered. Due to the size of sample, we did not validate the P4HA1 protein expression level in HNSCC tissues. Additionally, the role of P4HA1 in these pathways in the HNSCC is not completely clear. Thus, further studies are needed to explore underlying mechanism of P4HA1 in these pathways in the HNSCC.

5 | CONCLUSIONS

This integrated bioinformatics analysis provides strong evidence that increasing P4HA1 is significantly associated with HNSCC carcinogenesis and metastasis. Additionally, high P4HA1 expression is both a diagnostic biomarker and an independent prognostic factor for poor OS and RFS in HNSCC patients.

ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China (No. 81670920), the Zhejiang Provincial Natural Science Foundation of China (Nos. LY14H160003, LY15H130003, and LY19H160090), the Medical and Health Science Research Foundation of Zhejiang Province (Nos. 2016KYB272, 2018RC063, and 2019ZD018), the Medical and Health Training Project of Zhejiang Province (Nos. 2014PYA017 and 2015RCB025), the Scientific Innovation Team Project of Ningbo (No. 2012B82019), the Ningbo Natural Science Foundation (Nos. 2013A610217, 2015A610221, 2017A610236, 2018A610363, and 2018A610361), the Huimin Technology Research and Development Projects of Ningbo (No. 2015C50026), and the Ningbo Health Branding Subject Fund (PPXK2018-02). Thanks are due to the professional English language copy editing provided by American Journal Experts Company.

CONFLICTS OF INTEREST

None of the authors have any commercial or other associations that might pose a conflict of interest.

ORCID

Zhisen Shen https://orcid.org/0000-0001-6660-0488
Chongchang Zhou https://orcid.org/0000-0002-8728-6819

REFERENCES

1. Vigneswaran N, Williams MD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am. 2014;26(2):123-141.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
